Crossject Société Anonyme Valuation

Q: What is the Fair Price of ALCJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ALCJ (€1.98) is trading below our estimate of [[fair value]] (€35.16)

Is ALCJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALCJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALCJ (€1.98) is trading below our estimate of fair value (€35.16)

Significantly Below Fair Value: ALCJ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALCJ?

Key metric: As ALCJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALCJ. This is calculated by dividing ALCJ's market cap by their current revenue.
What is ALCJ's PS Ratio?
PS Ratio	35.9x
Sales	€2.36m
Market Cap	€84.68m

ALCJ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	43.6x
Enterprise Value/EBITDA	-7.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALCJ's PS Ratio compare to its peers?

The above table shows the PS ratio for ALCJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16.1x
AFME Affluent Medical	50.4x	-46.3%	€65.3m
GBT Guerbet	0.4x	6.1%	€330.4m
AMPLI Amplitude Surgical	1.5x	n/a	€155.4m
ALCOR Biocorp Production	12.1x	47.9%	€154.5m
ALCJ Crossject Société Anonyme	35.9x	87.1%	€84.7m

Price-To-Sales vs Peers: ALCJ is expensive based on its Price-To-Sales Ratio (35.9x) compared to the peer average (17.4x).

Price to Sales Ratio vs Industry

How does ALCJ's PS Ratio compare vs other companies in the FR Medical Equipment Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
GBT Guerbet	0.4x	6.1%	US$343.40m
ALBIO Biosynex	0.3x	n/a	US$30.99m
ALDMS Diagnostic Medical Systems	0.3x	n/a	US$14.03m
ALEMG Laboratoires Euromedis Société anonyme	0.4x	8.3%	US$13.71m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ALCJ is expensive based on its Price-To-Sales Ratio (35.9x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is ALCJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALCJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	35.9x
Fair PS Ratio	0.0006x

Price-To-Sales vs Fair Ratio: ALCJ is expensive based on its Price-To-Sales Ratio (35.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratoires Euromedis Société anonyme

€13.2m

Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.

ALEMG

€4.63

-2.9%

emeis Société anonyme

€839.2m

Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.

EMEIS

€5.21

-11.0%

-97.8%

Ramsay Générale de Santé

€1.3b

Operates healthcare facilities in France, Sweden, Norway, Denmark, and Italy.

GDS

€11.55

-4.1%

-42.5%